$5.34
+0.0 (+0.0%)
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$38.3M
ROE
-94.8%
Margin
-410.1%
D/E
0.00
Beta
2.03
52W
$3–$12
Wall Street Consensus
10 analysts · Apr 20263
Strong Buy
3
Buy
4
Hold
0
Sell
0
Strong Sell
60.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2025 | $-3.24 | $-0.82 | +$2.42 |
| Jun 2025 | $-2.91 | $-3.12 | $-0.21 |
| Mar 2025 | $-2.99 | $-2.20 | +$0.79 |
| Dec 2024 | $-3.07 | $-3.20 | $-0.13 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $7.6M | $4.2M | $8.7M | $765K | $1.6M |
| Net Income | -$15.3M | -$21.4M | -$14.8M | -$20.9M | -$5.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -91.1% | -75.8% | -91.1% | -91.1% | -94.8% | -94.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -2735.0% | -292.9% | -341.1% | -341.1% | -410.1% | -410.1% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 7.51 | 8.43 | 7.51 | 7.51 | 4.44 | 4.44 |
Key Ratios
ROA (TTM)
-34.1%
P/S (TTM)
2.51
P/B
0.8
EPS (TTM)
$-9.35
CF/Share
$-1.89
Rev Growth 3Y
+692.3%
52W High
$12.40
52W Low
$3.00
$3.00
52-Week Range
$12.40
Financial Health
Free Cash Flow
-$52.7M
Net Debt
$4.2M
Cash
$21.9M
Total Debt
$26.1M
As of Sep 30, 2025
How does GBIO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
GBIO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.5
▼
80%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
0.8
▼
67%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
GBIO profitability vs Biotechnology peers
ROE
-94.8%
▼
41%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-410.1%
▼
43%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-34.1%
▲
27%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
GBIO financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.4
▲
0%
above
peers
(4.4)
vs Peers
vs Industry
In line
Beta
2.0
▲
109%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
GBIO fundamentals radar
GBIO
Peer median
Industry
GBIO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GBIO vs peers: key metrics
Latest News
No related news yet